NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer
The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy).

This study will be performed in compliance with the study protocol, GCP (good clinical practice) and the applicable regulatory requirements.
Pancreas Cancer
DRUG: Neoadjuvant chemotherapy|PROCEDURE: surgery and Adjuvant chemotherapy
progression-free survival, period from study inclusion until the date of recurrence or surgery (in case of unresectability at surgical exploration)., from date of randomization until date of progression, assessed up to 5 years
histology, histological response,, at 6 months|overall survival, time from date of inclusion to date of death, From date of randomization until date of death, assessed up to 5 years|complication, complication rates after surgery,, until 6 months
The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy).

This study will be performed in compliance with the study protocol, GCP (good clinical practice) and the applicable regulatory requirements.